In SGLT2 diabetes fight, Lilly’s empagliflozin loss is J&J and AstraZeneca’s gain

Tracy Staton

Johnson & Johnson and AstraZeneca will just have to duke it out for share of the market for treatments for . A potential third competitor from Eli Lilly and Boehringer Ingelheim, , failed to win FDA approval, thanks to problems at a Boehringer manufacturing plant.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS